KENGREAL^® (cangrelor)
Health Economics and Value Team

Discover the potential clinical and economic outcomes of using KENGREAL

The KENGREAL Value Model

Using KENGREAL in high-risk and complex PCI cases may have an economic impact at your institution. The KENGREAL Value Model demonstrates how using KENGREAL versus clopidogrel (with or without GPIIb/IIIa) may affect health economics, considering the possible implications of ischemic and bleeding events across a 1- to 3-year horizon.

KENGREAL Value Model goals

Establish institution-specific baseline for anti-platelet therapy utilization

Identify the most valuable use criteria for KENGREAL

Demonstrate KENGREAL’s potential impact and budget implications in appropriate patient populations

Support monitoring with 6- to 12-month repeat analysis options

KENGREAL Value Model inputs and outputs

Content in this section is intended specifically for US population health decision makers who support patients undergoing PCI.

Click to Reveal

The KENGREAL Value Model applies inputs (e.g., patient characteristics as well as procedural, safety, and antiplatelet therapy data) to demonstrate potential outputs (e.g., economics and clinical outcomes) associated with using KENGREAL in PCI, including high-risk or complex cases.

The outputs in this model are subject to assumptions and methodology described within the model and the data the user selects or decides to input in the model. Calculations are based on patients undergoing PCI who, per the treating clinician, require a P2Y₁₂ inhibitor.

The model does not consider use of P2Y₁₂ agents other than clopidogrel.

Graphic showing the KENGREAL customer values, evidence-based impacts of using KENGREAL, patient risk stratification, and clinical decisions related to total cost. Values include clinical and economic impact of using KENGREAL, patient risk stratification, and clinical decisions related to the total cost of care. Evidence-based impacts include risk factors in high-risk acute coronary syndrome patients, patient populations with increased bleeding risk, economic implications and incidence of adverse events, and total cost of care. Other considerations include cardiovascular service-line and cath lab quality initiatives, bleeding avoidance strategy support, and standardization of care support.

The KENGREAL Value Model is considered health economics and value information. It is important to note that overall economic impact is dependent on specific patient populations, institutional practices, and local cost structures.

ACS=acute coronary syndrome; CV=cardiovascular; GPIIb/IIIa=glycoprotein IIb/IIIa inhibitor; PCI=percutaneous coronary intervention.

Explore the KENGREAL Value Model with a Health Economics and Value Specialist.

Get in Touch

This information can be provided to a payor, formulary committee, or other similar entity with knowledge and expertise in the area of the health economics analysis, carrying out its responsibilities for the selection of drugs for coverage or reimbursement.

Learn more about KENGREAL & the Value Model

Access information about KENGREAL clinical profile, pharmacology, and dosing

Visit KENGREAL.com

Connect with a Health Economics and Value Specialist today to learn more about the KENGREAL Value Model

Important Safety Information

KENGREAL^® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.

KENGREAL^® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.

Drugs that inhibit platelet P2Y₁₂ function, including KENGREAL^®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL^® than with clopidogrel. Bleeding complications with KENGREAL^® were consistent across a variety of clinically important subgroups. Once KENGREAL^® is discontinued, there is no antiplatelet effect after an hour.

The most common adverse reaction is bleeding.

Indication

KENGREAL^® (cangrelor) for Injection is a P2Y₁₂ platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y₁₂ platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

Please see Full Prescribing Information.

KENGREAL® (cangrelor)Health Economics and Value Team